Autoimmune Diseases News and Research RSS Feed - Autoimmune Diseases News and Research

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis. [More]
Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

It may seem counterintuitive, but exercise can be beneficial for people suffering from arthritis and other muscle and joint conditions. A new study at Hospital for Special Surgery finds that older adults experienced less pain, reduced stiffness and less fatigue after participating in a hospital-based exercise program. [More]
Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. [More]
Study: Key protein may help prevent tumor growth, promote wound healing

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports. [More]
MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). [More]
TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has enrolled the first patient in its phase IIb clinical trial of its lead product Ovasave in refractory Crohn’s disease. [More]
Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

One of the main obstacles to finding effective therapies for human diseases has been our limited understanding of disease pathogenesis: we lack detailed knowledge of the cellular and molecular mechanisms that lead to the development of disease. [More]
Researchers say that nervous system may play vital role in infections, autoimmune diseases

Researchers say that nervous system may play vital role in infections, autoimmune diseases

The nervous system may play a bigger role in infections and autoimmune diseases than previously known. If researchers can learn more about that role, it could provide insight into diagnosing and treating everything from the stomach flu to rheumatoid arthritis. [More]
Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted orphan medicinal product designation to ATX-F8-117 for the treatment of haemophilia A. [More]
NUS researchers make breakthrough discovery that could lead to future treatment for multiple sclerosis

NUS researchers make breakthrough discovery that could lead to future treatment for multiple sclerosis

A multi-disciplinary research team from the National University of Singapore has made a breakthrough discovery of a new type of immune cells that may help in the development of a future treatment for multiple sclerosis (MS). [More]
Early support and education program has positive impact on people with rheumatoid arthritis

Early support and education program has positive impact on people with rheumatoid arthritis

A study at Hospital for Special Surgery finds that a support group addressing the psychological and educational needs of people recently diagnosed with rheumatoid arthritis (RA) has a strong positive impact on their lives. [More]
Scientists identify four new genes associated with severe food allergy

Scientists identify four new genes associated with severe food allergy

Scientists have identified four new genes associated with the severe food allergy eosinophilic esophagitis (EoE). Because the genes appear to have roles in other allergic diseases and in inflammation, the findings may point toward potential new treatments for EoE. [More]
Moffitt announces development of innovative investigational biologic agent for MDS

Moffitt announces development of innovative investigational biologic agent for MDS

In a major step to treat patients living with Myelodysplastic Syndromes (MDS), a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases. [More]
Scientists identify how ADAR1 gene mutation can lead to diseases

Scientists identify how ADAR1 gene mutation can lead to diseases

Scientists have discovered how a gene mutation can lead to diseases that occur when the immune system attacks the body by mistake. [More]
BMI plays role in rheumatoid arthritis patients' ability to achieve sustained remission

BMI plays role in rheumatoid arthritis patients' ability to achieve sustained remission

A study by Hospital for Special Surgery researchers finds that body mass index (BMI) plays a role in rheumatoid arthritis (RA) patients' ability to achieve a sustained remission. Looking at patients who had received an RA diagnosis within the past 12 months, investigators found that those who were significantly underweight or overweight/obese were the least likely to remain in remission. [More]
Total hip replacement: An excellent option for younger patients with juvenile idiopathic arthritis

Total hip replacement: An excellent option for younger patients with juvenile idiopathic arthritis

When you think of hip replacement surgery, you generally envision an older adult with painful osteoarthritis. But the procedure is also used for younger patients with juvenile idiopathic arthritis (JIA) whose joints have been severely damaged by the disease. [More]
Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced that new data on Vectra DA will be featured at the 2014 American College of Rheumatology Annual Meeting, Nov. 15-19, 2014, in Boston, Massachusetts. [More]
Study points to major role of obesity in triggering, prolonging autoimmune diseases

Study points to major role of obesity in triggering, prolonging autoimmune diseases

Autoimmune diseases like Crohn's Disease and multiple sclerosis, in which the immune system attacks its own body rather than predatory invaders, affect 5-20% of the global community. A study published recently in Autoimmunity Reviews by Prof. Yehuda Shoenfeld, the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases at Tel Aviv University's Sackler Faculty of Medicine and Head of Zabludowicz Center for Autoimmune Diseases at Chaim Sheba Medical Center, Tel Hashomer, points to the major role obesity plays in triggering and prolonging these autoimmune diseases. [More]
Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2014. [More]
BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin. [More]